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ABSTRACT: Heparan sulfate (HS) glycosaminoglycans
participate in critical biological processes by modulating
the activity of a diverse set of protein binding partners.
Such proteins include all known members of the
chemokine superfamily, which are thought to guide the
migration of immune cells through their interactions with
HS. Here, we describe an expedient, divergent synthesis to
prepare deﬁned HS glycomimetics that recapitulate the
overall structure and activity of HS glycosaminoglycans.
Our approach uses a core disaccharide precursor to
produce a variety of diﬀerentially sulfated glycopolymers.
We demonstrate that a speciﬁc trisulfated mimetic
antagonizes the chemotactic activity of the proinﬂamma-
tory chemokine RANTES with potency similar to that of
heparin, without inhibiting serine proteases in the blood
coagulation cascade. Our work provides a general strategy
for modulating chemokine activity and dissecting the
pleiotropic functions of HS/heparin through the presenta-
tion of deﬁned sulfation motifs within polymeric scaﬀolds.
Heparan sulfate (HS) glycosaminoglycans are a ubiquitousclass of sulfated polysaccharides that are involved in
diverse physiological processes, such as development, wound
healing, angiogenesis, and inﬂammation.1 Assembled from
disaccharide subunits, HS polysaccharides exhibit subtle
variations in stereochemistry, length, and patterns of sulfation.
This structural diversity enables HS to modulate the activity of
>400 diﬀerent proteins, including ∼50 members of the
chemokine superfamily.2 Chemokines are chemoattractant
proteins that control the activation and migration of speciﬁc
leukocyte populations toward sites of injury, inﬂammation, and
atherosclerosis. Accumulation of pro-inﬂammatory chemokines
into epithelial spaces contributes to the pathogenesis of allergy,
arthritis, psoriasis, and other inﬂammatory disorders.3 Although
HS proteoglycans are required for establishing chemokine
gradients in vivo,4 the precise carbohydrate structural determi-
nants involved have yet to be elucidated, limiting the develop-
ment of HS-based strategies for targeting chemokine activity.
A major challenge to understanding the structure−activity
relationships of HS and developing HS-based therapeutic
approaches has been the chemical complexity and heterogeneity
of HS in vivo. Heparin, a close structural relative of HS, displays
less heterogeneity and is used clinically as an anti-coagulant drug
for the prevention and treatment of thrombosis.5 Elegant studies
have demonstrated that a unique sulfated sequence found within
heparin is primarily responsible for its anti-coagulant activity.6
Heparin has also been shown to have potent anti-inﬂammatory
activity in models of asthma, chronic dermatitis, and ulcerative
colitis, but it is not recommended as an anti-inﬂammatory agent
in clinical practice due to its anti-coagulant activity.7 Moreover,
heparin isolated from natural sources can induce other
undesirable physiological eﬀects due to its structural hetero-
geneity.6a The development of chemically deﬁned HS/heparin
mimetics that lack anti-coagulant activity oﬀers a potential
solution to these challenges. Although a few studies have
modiﬁed natural polysaccharides or undertaken the semi-
synthesis of glucan sulfate mimetics,8 such approaches lack the
precision of chemical synthesis9 in controlling the sulfation
sequence. To our knowledge, only one study9a exploited
chemical synthesis to generate complex, HS-based oligosacchar-
ides that modulate pro-inﬂammatory chemokines. Here, we
describe a new class of simpliﬁed HS/heparin glycomimetics that
have a highly tunable structure, controllable lengths, and deﬁned
sulfation motifs. Importantly, these molecules possess the ability
to inhibit pro-inﬂammatory chemokines with similar eﬃciency to
natural heparin, yet they do not interact with key factors in the
coagulation cascade.
Most chemokines have a primary HS-binding site occupied by
at least two sugar residues.10 Based on our prior work with
chondroitin sulfate glycosaminoglycans,11 we envisaged that HS
disaccharide epitopes appended onto a multivalent polymer
backbone might be suﬃcient to target this binding site, provided
that their binding aﬃnity could be enhanced through avidity
(Scheme 1a). A polynorbornene backbone was selected to allow
for maximal control over chain length and low polydispersity
through ring-opening metathesis polymerization chemistry
(Scheme 1b).12 Reduction of the unsaturated backbone was
expected to emulate the conformational plasticity found in native
HS/heparin and facilitate its interaction with proteins.13
Furthermore, by controlling the sulfation pattern prior to
polymerization, we sought to increase the speciﬁcity of the
polymers for particular HS-binding proteins. Notably, these
structures would represent the ﬁrst example of high-molecular-
weight polymers prepared from minimal HS disaccharide units.
A library of diﬀerentially sulfated glycopolymers 1−4 was
derived from a single synthetic precursor, 5 (Scheme 1b). The
orthogonal protecting group strategy for 5 was designed to allow
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multiple sulfation patterns to be accessed using a minimum
number of steps. We chose to install a tert-butyldimethylsilyl
(TBS) group at the C4′-hydroxyl and benzyl ethers (Bn) at the
non-sulfated positions C3′ and C3 to enhance the solubility of
the sulfated monomers during the polymerization step. Acetyl
(Ac) and levulinoyl (Lev) ester groups were selected for sites that
would ultimately carry the O-sulfonate groups (C2′ and C6,
respectively); the former group would also provide anchimeric
assistance in generating the 1,2-trans glycosidic linkage.
Disaccharide 5 was generated from iduronic acid (IdoA)
phosphate donor 6, glucosamine (GlcN) acceptor 7,14a and
norbornyl linker 8.12c An eﬃcient route to donor 6 and its
subsequent transformation to disaccharide 5 is shown in Scheme
2. First, the 1,2,4-triol 9 was synthesized from commercially
available diacetone glucose in six steps14b and treated with AcCl
and DMAP at −40 °C15a to aﬀord the triacetylated β-isomer 10
in quantitative yield. Conditions using Ac2O or higher
temperatures15b were avoided as they led to a mixture of α/β-
pyranose and α/β-furanose isomers. Anomeric bromination of
10 using TiBr4
15a formed a glycosyl halide intermediate, which
was directly transformed into 1,2-orthoester 11 using 2,4,6-
collidine as the base. The 1,2-orthoester moiety locked the
pyranose ring into the 4C1 conformation and allowed for
selective cleavage of the remaining acetyl group under Zempleń
conditions. After several unsuccessful attempts using standard
conditions, we found that TBS protection of the C4′ hydroxyl of
12 required excess TBSOTf in neat pyridine to compensate for
its poor nucleophilicity.
Direct reaction of orthoester 13 with acceptor 7 gave low
yields of the desired IdoA-GlcN disaccharide 14. We therefore
chose to explore the reactivity of the corresponding IdoA
phosphate donor, which could be accessed from 13 using
HOPO(OBu)2
16 in a single quantitative step. Fortuitously,
phosphate donor 6 reacted with acceptor 7 and stoichiometric
TMSOTf16 to deliver the α-linked disaccharide 14 in 93% yield.
To tether the HS disaccharide to norbornyl linker 8, we
converted 14 into glycosyl imidate 15 by deprotecting the
anomeric TBS and treating the resulting hemiacetal with
trichloroacetonitrile and DBU. Glycosidic coupling of 15 and 8
with catalytic TMSOTf resulted in a 1:1 mixture of α/β isomers;
however, treatment with BF3·OEt2 (0.34 equiv) gave exclusively
the β-isomer in 80% yield (δ = 4.34 ppm, J12 = 8 Hz).
Disaccharide 5 was then diversiﬁed into four diﬀerentially
sulfated polymers (1−4; Scheme 3). The azide was reduced
using 1,3-propanedithiol,9b and the resulting intermediate was
treated either with K2CO3 to deprotect both ester groups or with
hydrazine acetate9c to selectively cleave the Lev ester. The
resulting compounds 16 and 17 were regioselectivelyN-sulfated,
O-sulfated, and N-acetylated at the desired positions. Con-
veniently, we found that simultaneous sulfation at the O- and N-
positions could be achieved using SO3·Py and mild heating
conditions (55 °C). Polymerization of the sulfated monomers
with 5 mol % of Grubbs’ fast-initiating catalyst [(H2IMes)-
(Py)2(Cl)2RuCHPh]17 led to rapid conversion within
minutes to the desired glycopolymers (22−25). Late-stage
deprotection conditions were ﬁrst established usingmonomer 18
to prepare a monovalent trisulfated disaccharide bearing the
norbornyl linker at the reducing end (26, see SI) and then
applied to 22−25. We were pleased to ﬁnd that TMSOK-
mediated saponiﬁcation of the methyl ester also deprotected the
TBS group at C4′, likely due to its proximity to the resulting C5′
carboxylate anion. Finally, catalytic hydrogenation using Pd-
(OH)2/charcoal in a co-solvent of phosphate buﬀer and
methanol9b delivered 26 and glycopolymers 1−4, which were
characterized by 1H NMR spectroscopy and size exclusion
chromatography multi-angle light scattering. Comparison of the
1H−1H gCOSY NMR spectrum of trisulfated monomer 26 to
that of glycopolymer 1 conﬁrmed that the sulfation pattern
remained intact during the post-polymerization deprotection
steps. By varying the amount of catalyst, we could predictably
control the glycopolymer lengths within a relatively narrow
polydispersity range, aﬀording polymers with lengths compara-
ble to the length of commercially available heparin (Table S1).
With the library of glycopolymers in hand, we characterized
their binding speciﬁcities for RANTES, a basic chemokine that
induces the migration of T cells, monocytes, natural killer cells,
and other classes of leukocytes.18 Although RANTES preferen-
tially recognizes trisulfated heparin (Kd = 32.1 nM) over other
classes of glycosaminoglycans,19 the eﬀects of HS sulfation on
RANTES binding have not been examined using homogeneously
sulfated molecules. We compared the relative ability of each
glycopolymer to block RANTES binding to heparin (EC50 = 12.2
nM; Figure S1) using a competitive enzyme-linked immuno-
sorbent assay. Trisulfated glycopolymer 1 bound strongly to
RANTES (IC50 = 9.3 ± 1.1 μg/mL (334 ± 39 nM)), albeit with
reduced aﬃnity compared to heparin of similar chain length
(IC50 = 0.90± 0.03 μg/mL (45.0 ± 1.5 nM); Figure 1 and Table
Scheme 1. (a) Synthetic Mimetic of Heparin/HS
Polysaccharides and (b) Retrosynthesis of Glycopolymers 1−
4
Scheme 2. Synthesis of Disaccharide 5a
aReagents and conditions: (a) AcCl, Py, DMAP, CH2Cl2, −40 °C,
quant.; (b) (i) TiBr4, CH2Cl2, (ii) 2,4,6-collidine, MeOH, CH2Cl2,
75%; (c) NaOMe, MeOH, −10 °C, 80%; (d) TBSOTf, Py, 0 °C, 92%;
(e) HOPO(OBu)2, CH2Cl2, 4 Å MS, quant.; (f) TMSOTf, 7, CH2Cl2,
4 Å MS, 93%; (g) (i) TBAF, AcOH, THF, 0 °C, (ii) Cl3CCN, DBU,
CH2Cl2, 0 °C, 89%; (h) BF3·OEt2, 8, CH2Cl2, 4 Å MS, 80%.
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S2). However, the glycopolymer competed more eﬀectively for
RANTES binding compared to heparin at its maximum
inhibitory concentration. Whereas heparin exhibited a maximum
inhibition of 58.4%, 1 inhibited RANTES binding by up to 90.8%
under the same assay conditions, which could be attributed to
diﬀerences in their interactions with oligomeric forms of
RANTES.4 As expected, monovalent disaccharide 26 failed to
compete with heparin for RANTES binding (Figure 1). These
results provide the ﬁrst demonstration that an HS disaccharide
epitope can be suﬃcient for chemokine binding when presented
in a multivalent framework and underscore the importance of
avidity in the recognition of glycosaminoglycan structures.
Next, we tested whether site-deﬁned modiﬁcations to the
sulfation pattern of 1 would alter its aﬃnity for RANTES.
Removal of either the N-sulfate group of GlcN (2) or the 2-O-
sulfate group of IdoA (4) decreased binding to RANTES (IC50 =
31.1± 6.2 μg/mL (852± 170 nM) and 58.0± 5.7 μg/mL (1760
± 170 nM), respectively), and unsulfated 3 had no appreciable
activity (Figure 1a). The observation that removal of 2-O-
sulfation has a greater eﬀect than removal ofN-sulfation suggests
that precise positioning of the sulfate groups (in addition to
overall charge) is important for determining the aﬃnity of the
glycopolymers for RANTES. Importantly, none of the
glycopolymers possessed anti-coagulant activity, as demonstra-
ted by their inability to potentiate the inhibition of factor Xa and
thrombin substrates by antithrombin III (Figures 1b and S2).
Thus, controlling the positioning of sulfate groups within the
glycopolymer enables the anti-inﬂammatory function of HS/
heparin to be dissected from its anti-coagulant function.
Furthermore, modiﬁcations to the sulfation pattern can be
exploited to adjust the aﬃnity of the glycopolymers for diﬀerent
HS-binding proteins and may facilitate the development of
glycosaminoglycan-based therapeutic agents with fewer oﬀ-
target side eﬀects.
The chemotactic activity of RANTES, which is essential to the
pathogenesis of allergic inﬂammatory responses such as asthma,
is mediated in part by the G-protein coupled receptor CCR3.20
To test whether 1 can interfere with RANTES-induced
chemotaxis via CCR3, we probed the migration of murine L1.2
pre-B cells that were stably transfected with the CCR3
receptor.20a Using a modiﬁed Boyden chamber, we observed
that the directional migration of L1.2-CCR3 cells (but not wild-
type L1.2 cells lacking CCR3) was dependent on the RANTES
concentration and elicited a maximal response at 10 nM (Figure
S3). Pre-incubation of RANTES (10 nM) with either 1 or
heparin diminished the chemotactic activity of RANTES in a
dose-dependent manner (Figure 2). Further corroborating these
results, lower levels of RANTES were detected on the surface of
CCR3-expressing cells after the chemokine (100 nM) was
pretreated with 1 or heparin, as determined by ﬂow cytometry
Scheme 3. Synthesis of Glycopolymers 1−4a
aReagents and conditions: (a) 1,3-propanedithiol, DIPEA, MeOH, 87%; (b) K2CO3, MeOH, 78%; (c) H2NNH2·H2O, AcOH, Py, quant.; (d)
SO3·Py, NEt3, Py, 55 °C, 78−85%; (e) Ac2O, NEt3, MeOH, quant.; (f) (H2IMes)(Py)2(Cl)2RuCHPh, DCE, MeOH, quant.; (g) (i) TMSOK,
TBAI, THF, 80−88%, (ii) Pd(OH)2/charcoal, H2 (1 atm), phosphate buﬀer (pH 7.4), MeOH, 37−55%.
Figure 1. (a) Comparison of the ability of 1−4 to compete with heparin
for binding to RANTES. P < 0.05 for IC50 values of 2 and 4 compared to
1; P < 0.05 for IC50 value of 2 compared to 4. IC50 values corrected for
ligand valence are reported in Table S2. (b) 1−4 do not potentiate the
anti-coagulant activity of antithrombin III, as determined by their ability
to inhibit factor Xa substrates in a chromogenic assay. Data represent the
mean ± standard error for quadruplicate assays in (a) and (b).
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analysis (Figure S4). Notably, 1 and heparin failed to block the
migration of L1.2 cells transfected with CCR5, an alternative
receptor for RANTES (Figure S5). Consistent with these
ﬁndings, the reported binding sites for HS and RANTES overlap
on CCR3, whereas the two binding sites share no overlap on
CCR5.20b Together, our results show that 1 eﬀectively
antagonizes the CCR3-dependent chemotactic activity of
RANTES in cells, with comparable potency as heparin.
Moreover, we demonstrate the ability of these HS glycomimetics
to selectively target speciﬁc chemokine−receptor interactions.
In conclusion, we have developed a new class of HS
glycomimetics that are synthetically accessible and highly tunable
in structure and sulfation sequence. By controlling the sulfation
sequence and exploiting the principles of multivalency to
enhance glycan recognition, the binding aﬃnity of HS
disaccharides for protein binding partners can be ampliﬁed to
target chemokines and their receptor interactions. We
demonstrate that a trisulfated HS glycopolymer binds to
RANTES with nanomolar aﬃnity and inhibits the CCR3-
dependent cellular response to this therapeutically important
chemokine, without aﬀecting components of the blood
coagulation cascade. We envision that variations of these
glycomimetics can be synthetically tailored to antagonize a
wide range of HS-binding proteins with clinical relevance to
atherosclerosis, cancer, and autoimmune disorders.
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(6) (a) Petitou, M.; Heŕault, J. P.; Bernat, A.; Driguez, P. A.;
Duchaussoy, P.; Lormeau, J. C.; Herbert, J. M. Nature 1999, 398, 417.
(b) Choay, J.; Petitou, M.; Lormeau, J. C.; Sinay, P.; Casu, B.; Gatti, G.
Biochem. Biophys. Res. Commun. 1983, 116, 492. (c) Xu, Y.; Masuko, S.;
Takieddin, M.; Xu, H.; Liu, R.; Jing, J.; Mousa, S. A.; Linhardt, R. J.; Liu,
J. Science 2011, 334, 498.
(7) Young, E. Thromb. Res. 2008, 122, 743.
(8) (a) Wang, L. C.; Brown, J. R.; Varki, A.; Esko, J. D. J. Clin. Invest.
2002, 110, 127. (b) Wang, J.-G.; Mu, J.-S.; Zhu, H.-S.; Geng, J.-G.
Inflamm. Res. 2002, 51, 435. (c) Alban, S.; Ludwig, R. J.; Bendas, G.;
Schön, M. P.; Oostingh, G. J.; Radeke, H. H.; Fritzsche, J.; Pfeilschifter,
J.; Kaufmann, R.; Boehncke, W.-H. J. Invest. Derm. 2009, 129, 1192.
(d) Powell, A. L.; Ahmed, Y. A.; Yates, E. A.; Turnbull, J. E. Nat. Protoc.
2010, 5, 821.
(9) (a) de Paz, J. L.; Moseman, E. A.; Noti, C.; Polito, L.; von Andrian,
U. H.; Seeberger, P. H. ACS Chem. Biol. 2007, 2, 735. (b) Hu, Y.-P.;
Zhong, Y.-Q.; Chen, Z.-G.; Chen, C.-Y.; Shi, Z.; Zulueta, M. M.; Ku, C.-
C.; Lee, P.-Y.; Wang, C.-C.; Hung, S.-C. J. Am. Chem. Soc. 2012, 134,
20722. (c) Fan, R.-H.; Achkar, J.; Hernańdez-Torres, J. M.; Wei, A. Org.
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